½ÃÀ庸°í¼­
»óǰÄÚµå
1679199

È÷¾Ë·ç·Ð»ê ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°, Á¦Á¦, À¯Åë ä³Î, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ¼¼°è ºÐ¼®

Hyaluronic Acid Market Forecasts to 2030 - Global Analysis By Product, Formulation, Distribution Channel, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀåÀº 2024³â¿¡ 15¾ï 2,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß CAGR 9.8%·Î ¼ºÀåÇϸç 2030³â¿¡´Â 27¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

È÷¾Ë·ç·Ð»êÀº ÁÖ·Î °áÇÕÁ¶Á÷, ÇǺÎ, °üÀý¿¡ Á¸ÀçÇϴ õ¿¬ ¹°ÁúÀÔ´Ï´Ù. È÷¾Ë·ç·Ð»êÀº ±Û¸®ÄÚ»ç¹Ì³ë±Û¸®Ä­À¸·Î ¼öºÐÀ» º¸À¯ÇÏ´Â ´É·ÂÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ¼öºÐ °ø±Þ, À±È°, ź·ÂÀ» Á¦°øÇϸç, HA´Â ÇǺΠº¸½ÀÀ» °³¼±Çϰí ÁÖ¸§À» ÁÙÀ̰í ÅÊÅÊÇÏ°Ô ÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °üÀýÀ» À±È°ÇÏ¿© °ñ°üÀý¿° Ä¡·á¿¡ µµ¿òÀÌ µÇ¸ç, ´« ¼ö¼ú¿¡µµ »ç¿ëµË´Ï´Ù. ¼öºÐ °áÇÕ Æ¯¼ºÀº ÇǺΠ°Ç°­°ú Á¶Á÷ ÀüüÀÇ ±â´É À¯Áö¿¡ ÇʼöÀûÀÔ´Ï´Ù.

OARSI(Osteoarthritis Research Society International)¿¡ µû¸£¸é ºñ½ºÄÚ º¸ÃæÁ¦ ó¹æÀÇ ¾à 90%´Â °ñ°üÀý¿° Ä¡·á¸¦ À§ÇÑ ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å¿Í È÷¾Ë·ç·Ð»ê ÁÖ»ç¾àÀÔ´Ï´Ù.

¾ÈƼ¿¡ÀÌ¡ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

HA´Â ´õ¸» ÇÊ·¯, Å©¸² ¹× ´õ¸» ÇÊ·¯ÀÇ ÁÖ¿ä ¼ººÐÀ¸·Î ¼öºÐÀ» À¯ÁöÇϰí, ÁÖ¸§À» ÁÙÀ̰í, ÇǺΠź·ÂÀ» Çâ»ó½ÃŰ´Â ´É·ÂÀ¸·Î À¯¸íÇÕ´Ï´Ù. °í·ÉÈ­ Àα¸ Áõ°¡, ¹Ì¿ë¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ºñħ½ÀÀû ¹Ì¿ë Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ HA ±â¹Ý Á¦Ç° ÆÇ¸Å¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ºÅ²Äɾî ó¹æÀÇ ¹ßÀü°ú ÇǺΰú Àü¹®ÀÇÀÇ ÃßõÀÌ ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. È­Àåǰ »ê¾÷ÀÇ È®Àå, E-Commerce Ç÷§Æû, ¼Ò¼È¹Ìµð¾îÀÇ ¿µÇâ·Âµµ HA ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ¿© HA°¡ ½ºÅ²ÄÉ¾î ¼ººÐÀ¸·Î ¾ÐµµÀûÀÎ Á¸Àç°¨À» µå·¯³»°í ÀÖ½À´Ï´Ù.

ÀáÀçÀû ºÎÀÛ¿ë

È÷¾Ë·ç·Ð»ê(HA)Àº ƯÈ÷ ´õ¸» ÇÊ·¯¿Í °°Àº ÁÖÀÔ Ä¡·á¿¡¼­ ¹ßÀû, ºÎÁ¾, ¾Ë·¹¸£±â ¹ÝÀÀ, °¨¿°°ú °°Àº ÀáÀçÀû ºÎÀÛ¿ëÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. µå¹°°Ô´Â ºÎÀûÀýÇÑ Åõ¿©°¡ µ¢¾î¸®, Ç÷°üÆó»ö, ÇÊ·¯ÀÇ À̵¿À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ÈÀü¼º ¹®Á¦, Àϰü¼º ¾ø´Â °á°ú, ¹Ýº¹ÀûÀÎ Ä¡·áÀÇ Çʿ伺À¸·Î ÀÎÇØ Àå±â°£ »ç¿ëÀ» ²¨·ÁÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À§ÇèÀº ¼ÒºñÀÚ ºÒ¾È°ú ±ÔÁ¦ ¹®Á¦¸¦ ¾ß±âÇÏ°í ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

°ñ°üÀý¿° Ä¡·á¿¡ ´ëÇÑ »ç¿ë Áõ°¡

ºñ½ºÄÚ½º º¸ÃæÁ¦·Î ¾Ë·ÁÁø HA ÁÖ»ç´Â °üÀýÀÇ À±È°°ú Äí¼ÇÀ» µ½°í ÅëÁõÀ» ¿ÏÈ­Çϰí À̵¿¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. Àα¸ÀÇ °í·ÉÈ­¿Í ÁÂ½Ä »ýȰ·Î ÀÎÇØ °ñ°üÀý¿° ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºñ¼ö¼úÀû, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸°³¹ßÀÇ ¹ßÀü°ú FDAÀÇ ½ÂÀÎÀ¸·Î Á¦Ç°ÀÇ °¡¿ë¼º°ú È¿´ÉÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ HA ±â¹Ý Ä¡·á´Â ÁøÅëÁ¦ ¹× ¼ö¼ú¿¡ ´ëÇÑ È¿°úÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ±× äÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

³ôÀº Á¦Ç° ºñ¿ë

È÷¾Ë·ç·Ð»êÀº º¹ÀâÇÑ ¹ßÈ¿¸¦ ±â¹ÝÀ¸·Î ÇÑ ÃßÃâ, Á¤Á¦, ǰÁú°ü¸® °úÁ¤À¸·Î ÀÎÇØ »ý»ê ºñ¿ëÀÌ ³ô½À´Ï´Ù. ½ºÅ²ÄÉ¾î ¹× ÀǾàǰ ¿ëµµÀÇ ÀÇ·á¿ë ¶Ç´Â °í¼øµµ HAÀÇ »ý»ê¿¡´Â ÷´Ü »ý¸í°øÇÐ ±â¼úÀÌ ÇÊ¿äÇϸç, ÀÌ´Â Á¦Á¶ ºñ¿ëÀ» Áõ°¡½Ãŵ´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ß ÅõÀÚ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, Ư¼öÇÑ Á¦Çü µîÀÌ ºñ¿ëÀ» Áõ°¡½Ãŵ´Ï´Ù. ±× °á°ú, ƯÈ÷ ±¸¸Å·ÂÀÌ ³·Àº ½ÅÈï ±¹°¡ ½ÃÀå¿¡¼­´Â Á¢±Ù¼º°ú °æÁ¦¼ºÀÌ Á¦ÇѵǾî Àüü ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ:

COVID-19 ÆÒµ¥¹ÍÀº °ø±Þ¸Á Áß´Ü, ¼±ÅÃÀû ½Ã¼ú °¨¼Ò, È­Àåǰ ¼Òºñ ÁöÃâ °¨¼Ò·Î ÀÎÇØ Ãʱâ È÷¾Ë·ç·Ð»ê ½ÃÀåÀ» È¥¶õ¿¡ ºü¶ß·È½À´Ï´Ù. Æó¼â·Î ÀÎÇØ ´õ¸» ÇÊ·¯¿Í °°Àº ¹Ì¿ë ½Ã¼úÀÌ °¨¼ÒÇß½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ÀÌÈÄ È¸º¹µÇ¸é¼­ ½ºÅ²Äɾî, À£´Ï½º, ÃÖ¼Òħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ °ñ°üÀý¿° ¹× ¾È°ú Ä¡·á¸¦ Æ÷ÇÔÇÑ ÀÇ·á ºÐ¾ß´Â ÀÇ·á ½Ã½ºÅÛÀÌ ±ä±ÞÇÏÁö ¾ÊÀº ½Ã¼úÀ» Àç°³ÇÔ¿¡ µû¶ó ȸº¹µÇ¾î ½ÃÀå ¼ºÀåÀ» ¾ÈÁ¤È­½ÃÄ×½À´Ï´Ù.

¿¹Ãø ±â°£ Áß °íºÐÀÚ È÷¾Ë·ç·Ð»ê ºÎ¹®ÀÌ °¡Àå Å« ºÎ¹®ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°íºÐÀÚ È÷¾Ë·ç·Ð»ê ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, HMW-HA´Â ÀϹÝÀûÀ¸·Î 1,000kDa ÀÌ»óÀÇ Å« ºÐÀÚ »ç½½À» °¡Áø È÷¾Ë·ç·Ð»êÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ¼öºÐÀ» À¯ÁöÇϰí, ÇǺΠº¸½ÀÀ» °­È­Çϰí, º¸È£ À庮À» Çü¼ºÇÏ¿© »óó Ä¡À¯¸¦ ÃËÁøÇÕ´Ï´Ù. °­·ÂÇÑ Ç׿°Áõ ÀÛ¿ëÀÌ ÀÖÀ¸¸ç, »êÈ­ ½ºÆ®·¹½º °¨¼Ò¿¡ µµ¿òÀÌ µË´Ï´Ù. ÇǺΠ°ü¸®¿¡ ÀÚÁÖ »ç¿ëµÇ¸ç, ¿À·£ ½Ã°£ µ¿¾È ¼öºÐÀ» °ø±ÞÇϰí ÅÊÅÊÇÏ°Ô ÇÏ´Â È¿°ú°¡ ÀÖ½À´Ï´Ù.

ÆÛ½º³ÎÄÉ¾î ¹× ºäƼ ºÐ¾ß´Â ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹Ãø ±â°£ Áß ÆÛ½º³ÎÄÉ¾î ¹× ºäƼ ºÐ¾ß´Â ¶Ù¾î³­ º¸½À ¹× ³ëÈ­ ¹æÁö Ư¼ºÀ¸·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼öºÐÀ» ²ø¾î´ç±â°í ¼öºÐÀ» À¯ÁöÇÏ¿© ÇǺθ¦ ´õ ÅÊÅÊÇÏ°í ¸Å²ô·´°í Àþ¾î º¸ÀÌ°Ô ÇÕ´Ï´Ù. ¼¼·³, Å©¸², ¸¶½ºÅ©¿¡ ÇÔÀ¯µÇ¾î ÀÜÁÖ¸§À» ¾ø¾Ö°í, ź·ÂÀ» ³ôÀ̰í, ÇǺÎÀÇ °ÅÄ¥¾îÁüÀ» ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ½ºÅ²ÄÉ¾î ¹× È­Àåǰ ó¹æ¿¡¼­ ±× Àαâ´Â Àü ¼¼°è¿¡¼­ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª:

¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ºÅ²Äɾ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¾ÈƼ¿¡ÀÌ¡ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·á¿ë ¿ëµµ È®´ë·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹, ÀϺ», Çѱ¹, Àεµ µîÀÇ ±¹°¡µéÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ¹Ì¿ë »ê¾÷ÀÇ È£È²°ú ³ôÀº ¹Ì¿ë ½Ã¼ú äÅ÷üÀÌ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ ´õ¸» ÇÊ·¯¿Í °ñ°üÀý¿° Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿À±â¼úÀÇ ¹ßÀüÀÌ Á¦Ç° ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ K-ºäƼ¿Í J-ºäƼÀÇ À¯ÇàÀº HA ±â¹Ý ½ºÅ²ÄɾîÀÇ ÆÇ¸Å¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¿¹Ãø ±â°£ Áß ºÏ¹Ì´Â ³ëÈ­ ¹æÁö ½ºÅ²Äɾî, ´õ¸» ÇÊ·¯, °ñ°üÀý¿° Ä¡·á¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹Àº Àß È®¸³µÈ ¹Ì¿ë ¹× ÇコÄÉ¾î »ê¾÷, ¹ÌÀÇ½Ä Áõ°¡, ÃÖ¼Òħ½À ¼ö¼ú Áõ°¡·Î ÀÎÇØ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¶ÇÇÑ HA¸¦ ±â¹ÝÀ¸·Î ÇÑ ¾È°ú ¹× ¼ºÇü¿Ü°ú Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ôÀº Áö¿ªÀÔ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä »ê¾÷ ±â¾÷ÀÇ Á¸Àç¿Í R&D ÅõÀÚ Áõ°¡´Â ½ÃÀåÀÇ ¼ºÀå ±Ëµµ¸¦ ´õ¿í Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´¿¡°Ô´Â ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ Á¦°øÇÕ´Ï´Ù. :

  • ±â¾÷¼Ò°³
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3»ç)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(ÃÖ´ë 3»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¿ªÀû ÀÔÁö, Àü·«Àû Á¦ÈÞ¿¡ ±â¹ÝÇÑ ÁÖ¿ä ±â¾÷ÀÇ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç ¾îÇÁ·ÎÄ¡
  • Á¶»ç Á¤º¸¿ø
    • 1Â÷ Á¶»ç Á¤º¸¿ø
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀå : Á¦Ç°º°

  • °íºÐÀÚ·® È÷¾Ë·ç·Ð»ê
  • ÁߺÐÀÚ·® È÷¾Ë·ç·Ð»ê
  • ÀúºÐÀÚ·® È÷¾Ë·ç·Ð»ê

Á¦6Àå ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀå : Á¦Á¦º°

  • ÁÖ»ç
  • ±¹¼Ò
  • °æ±¸

Á¦7Àå ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀå : À¯Åë ä³Îº°

  • E-Commerce Ç÷§Æû
  • ½´ÆÛ¸¶ÄÏ/ÇÏÀÌÆÛ¸¶ÄÏ
  • ¾à±¹¡¤µå·¯±×½ºÅä¾î
  • Àü¹®Á¡
  • ±âŸ À¯Åë ä³Î

Á¦8Àå ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀå : ¿ëµµº°

  • ½Äǰ ¹× ½ÄÀ̺¸ÃæÁ¦
  • ¾È°ú
  • Á¤Çü¿Ü°ú
  • ÀǾàǰ
  • ÆÛ½º³ÎÄɾî¿Í ¹Ì¿ë
  • ±âŸ ¿ëµµ

Á¦9Àå ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¹Ì¿ë Ŭ¸®´Ð
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ¿¬±¸±â°ü
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦10Àå ¼¼°èÀÇ È÷¾Ë·ç·Ð»ê ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕº´»ç¾÷
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Allergan Corporation
  • Sanofi Corporation
  • Evonik Industries AG
  • Bloomage Biotechnology Corporation Limited
  • Seikagaku Corporation
  • Anika Therapeutics, Inc.
  • LG Chem
  • Lubrizol Corporation
  • Royal DSM
  • Kewpie Corporation
  • Symatese Group
  • HTL Biotechnology
  • FocusChem Biotech
  • Croda International Plc
  • Stanford Chemicals Company
  • Maruha Nichiro Corporation
  • Evolus, Inc.
  • Contipro a.s.
  • Fidia Farmaceutici S.p.A.
  • Zimmer Biomet
KSA 25.04.09

According to Stratistics MRC, the Global Hyaluronic Acid Market is accounted for $1.52 billion in 2024 and is expected to reach $2.71 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Hyaluronic acid is a naturally occurring substance found in the human body, primarily in connective tissues, skin, and joints. It is a glycosaminoglycan known for its ability to retain water, providing hydration, lubrication, and elasticity. HA is widely used to improve skin hydration, reduce wrinkles, and enhance plumpness. It helps treat osteoarthritis by lubricating joints and is used in eye surgeries. Its moisture-binding properties make it essential for maintaining skin health and overall tissue function.

According to the Osteoarthritis Research Society International (OARSI), nearly 90% of visco supplement prescriptions consists of both corticosteroids and hyaluronic acid injections to treat osteoarthritis.

Market Dynamics:

Driver:

Rising demand for anti-aging products

HA is a key ingredient in serums, creams, and dermal fillers, known for its ability to retain moisture, reduce wrinkles, and enhance skin elasticity. The growing aging population, increasing beauty consciousness, and preference for non-invasive cosmetic treatments further boost HA-based product sales. Additionally, advancements in skincare formulations and endorsements by dermatologists fuel consumer trust. The expansion of the cosmetic industry, e-commerce platforms, and social media influence also accelerates HA market growth, making it a dominant skincare ingredient.

Restraint:

Potential side effects

Hyaluronic acid (HA) may cause potential side effects such as redness, swelling, allergic reactions, or infections, especially with injectable treatments like dermal fillers. In rare cases, improper administration can lead to lumps, vascular occlusion, or migration of fillers. Additionally, safety issues, inconsistent results, and the need for repeated treatments discourage long-term use. These risks create consumer concerns and regulatory challenges, hampering market growth.

Opportunity:

Growing use in osteoarthritis treatment

HA injections, known as visco supplementation, help lubricate and cushion joints, reducing pain and improving mobility. As osteoarthritis cases rise due to aging populations and sedentary lifestyles, demand for non-surgical, minimally invasive treatments increases. Ongoing R&D advancements and FDA approvals enhance product availability and effectiveness. Additionally, HA-based therapies offer an effective alternative to painkillers and surgeries, further boosting adoption.

Threat:

High product costs

Hyaluronic acid has high production costs due to its complex fermentation-based extraction, purification, and quality control processes. Producing medical-grade or high-purity HA for skincare and pharmaceutical applications requires advanced biotechnology, increasing manufacturing expenses. Additionally, R&D investments, regulatory approvals, and specialized formulations add to the cost. As a result, restricted accessibility and affordability hinder overall market expansion, especially in developing regions with lower purchasing power.

Covid-19 Impact:

The covid-19 pandemic initially disrupted the hyaluronic acid market due to supply chain interruptions, reduced elective procedures, and lower consumer spending on cosmetics. Lockdowns led to a decline in aesthetic treatments like dermal fillers. However, post-pandemic recovery saw increased demand for skincare, wellness, and minimally invasive procedures. Additionally, the medical segment, including osteoarthritis and ophthalmic treatments, rebounded as healthcare systems resumed non-urgent procedures, stabilizing market growth.

The high molecular weight hyaluronic acid segment is expected to be the largest during the forecast period

The high molecular weight hyaluronic acid segment is expected to account for the largest market share during the forecast period. HMW-HA is a form of hyaluronic acid with large molecular chains, typically above 1,000 kDa. It retains moisture, enhances skin hydration, and promotes wound healing by forming a protective barrier. It has strong anti-inflammatory properties and helps in reducing oxidative stress. Commonly found in skincare, it provides long-lasting hydration and plumping effects.

The personal care & beauty segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the personal care & beauty segment is predicted to witness the highest growth rate due to its exceptional hydrating and anti-aging properties. It attracts and retains moisture, making skin plumper, smoother, and more youthful. Found in serums, creams, and masks, it helps reduce fine lines, improves elasticity, and soothes irritation. Its popularity continues to grow in skincare and cosmetic formulations worldwide.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising skincare awareness, increasing demand for anti-aging products, and expanding medical applications. Countries like China, Japan, South Korea, and India lead the market, driven by a booming beauty industry and high adoption of cosmetic procedures. The region's aging population fuels demand for dermal fillers and osteoarthritis treatments, while advancements in biotechnology enhance product innovation. Additionally, the popularity of K-beauty and J-beauty trends boosts HA-based skincare sales.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by consumer demand for anti-aging skincare, dermal fillers, and osteoarthritis treatments. The U.S. dominates the market due to a well-established cosmetic and healthcare industry, increasing aesthetic consciousness, and rising minimally invasive procedures. The region also sees strong adoption of HA-based ophthalmic and orthopedic treatments. Additionally, the presence of key industry players and increasing R&D investments further support the market's growth trajectory.

Key players in the market

Some of the key players in Hyaluronic Acid market include Allergan Corporation, Sanofi Corporation, Evonik Industries AG, Bloomage Biotechnology Corporation Limited, Seikagaku Corporation, Anika Therapeutics, Inc., LG Chem, Lubrizol Corporation, Royal DSM, Kewpie Corporation, Symatese Group, HTL Biotechnology, FocusChem Biotech, Croda International Plc, Stanford Chemicals Company, Maruha Nichiro Corporation, Evolus, Inc., Contipro a.s., Fidia Farmaceutici S.p.A. and Zimmer Biomet.

Key Developments:

In October 2024, Evolus, Inc. announced that it received EU Medical Device Regulation (MDR) certification for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme(R). This certification allows Evolus to enter the European dermal filler market, doubling its addressable market outside the U.S. to $1.8 billion.

In July 2024, Bloomage, a global leader in hyaluronic acid and bioactive substances, introduced MitoPQQ(TM) at the IFT FIRST Expo. This water-soluble compound, naturally found in various foods, enhances mitochondrial function, combats cellular aging, and supports cognitive health. Produced through fermentation, MitoPQQ(TM) is non-GMO and certified by GRAS, KOSHER, and HALAL standards.

Products Covered:

  • High Molecular Weight Hyaluronic Acid
  • Medium Molecular Weight Hyaluronic Acid
  • Low Molecular Weight Hyaluronic Acid

Formulations Covered:

  • Injectable
  • Topical
  • Oral

Distribution Channels Covered:

  • E-commerce Platforms
  • Supermarkets/Hypermarkets
  • Pharmacies & Drug Stores
  • Specialty Stores
  • Other Distribution Channels

Applications Covered:

  • Food & Dietary Supplements
  • Ophthalmology
  • Orthopedics
  • Pharmaceuticals
  • Personal Care & Beauty
  • Other Applications

End Users Covered:

  • Hospitals
  • Aesthetic Clinics
  • Biotechnology Companies
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyaluronic Acid Market, By Product

  • 5.1 Introduction
  • 5.2 High Molecular Weight Hyaluronic Acid
  • 5.3 Medium Molecular Weight Hyaluronic Acid
  • 5.4 Low Molecular Weight Hyaluronic Acid

6 Global Hyaluronic Acid Market, By Formulation

  • 6.1 Introduction
  • 6.2 Injectable
  • 6.3 Topical
  • 6.4 Oral

7 Global Hyaluronic Acid Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 E-commerce Platforms
  • 7.3 Supermarkets/Hypermarkets
  • 7.4 Pharmacies & Drug Stores
  • 7.5 Specialty Stores
  • 7.6 Other Distribution Channels

8 Global Hyaluronic Acid Market, By Application

  • 8.1 Introduction
  • 8.2 Food & Dietary Supplements
  • 8.3 Ophthalmology
  • 8.4 Orthopedics
  • 8.5 Pharmaceuticals
  • 8.6 Personal Care & Beauty
  • 8.7 Other Applications

9 Global Hyaluronic Acid Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Aesthetic Clinics
  • 9.4 Biotechnology Companies
  • 9.5 Research Institutions
  • 9.6 Other End Users

10 Global Hyaluronic Acid Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.10 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.10 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.1 Middle East & Africa
    • 10.10.1 Saudi Arabia
    • 10.10.2 UAE
    • 10.10.3 Qatar
    • 10.10.4 South Africa
    • 10.10.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Allergan Corporation
  • 12.2 Sanofi Corporation
  • 12.3 Evonik Industries AG
  • 12.4 Bloomage Biotechnology Corporation Limited
  • 12.5 Seikagaku Corporation
  • 12.6 Anika Therapeutics, Inc.
  • 12.7 LG Chem
  • 12.8 Lubrizol Corporation
  • 12.9 Royal DSM
  • 12.10 Kewpie Corporation
  • 12.11 Symatese Group
  • 12.12 HTL Biotechnology
  • 12.13 FocusChem Biotech
  • 12.14 Croda International Plc
  • 12.15 Stanford Chemicals Company
  • 12.16 Maruha Nichiro Corporation
  • 12.17 Evolus, Inc.
  • 12.18 Contipro a.s.
  • 12.19 Fidia Farmaceutici S.p.A.
  • 12.20 Zimmer Biomet
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦